Evidence map›Paper›PMID 42506676›Full record

ArticleVaccines2026

Challenges and Future Perspectives for Vaccines Targeting the Tumor Microenvironment.

Devin B Lowe, Neda Feizi, Walter J Storkus

Abstract readEditorial
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Devin B LoweDepartment of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA.
Neda FeiziDepartment of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Walter J StorkusDepartment of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0001-8961-4444

Funding

NIH HHS 1R01 CA249811-01A1the TTUHSC Rural Cancer Collaborative
6 · The paper itself

Abstract

Immunotherapies integrating immune checkpoint inhibitors (ICI) represent the current standard of care for many solid cancers, yet they effectively treat only a minority of patients due to intrinsic or acquired resistance mechanisms [...].

Identifiers

PMID42506676
PMCPMC13431399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.